U.S. FDA approves ImmunityBio's bladder cancer therapy
The U.S. FDA approved ImmunityBio's IBRX combination therapy to treat a type of bladder cancer, the regulator said on Monday, which would help bring the company's first product to market.
The U.S. FDA approved ImmunityBio's IBRX combination therapy to treat a type of bladder cancer, the regulator said on Monday, which would help bring the company's first product to market.